Download PDF
Drug Res (Stuttg) 2016; 66(08): 415-419
DOI: 10.1055/s-0042-107943
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Pre-formulation Study of Salicylidine-cephalexin-Zn(II) dihydrate, a New Derivative of Cefalexin

M. S. Iqbal
1   Deparment of Chemistry, Forman Christian College, Lahore, Pakistan
,
A. H. Khan
2   Department of Pharmacy, Forman Christian College, Lahore, Pakistan
› Author Affiliations
Further Information

Publication History

received 08 April 2016

accepted 27 April 2016

Publication Date:
30 May 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Salicylidine-cefalexin-Zn(II)·2H2O, a new derivative of cefalexin, has been reported to possess enhanced anti-microbial activity and lower toxicity than cefalexin. It is, therefore, desirable to carry out a pre-formulation study to determine its pharmaceutical properties which will be useful in conversion of the new molecule into various dosage forms.

Methods: The compound was synthesized by the previously reported method and characterized by elemental, Fourier-transform infrared and electronic spectral analyses. Crystallinity was determined by powder x-ray diffraction. Particle size distribution was determined by a laser-based sizer. Other properties including flow, density and compaction strength were determined by use of appropriate standard methods. The compound was also evaluated as a prodrug through dissolution study by the USP method.

Results: It was found that the new derivative is an amorphous powder with different bulk density, porosity, compressibility, plasticity and flow properties as compared to cefalexin. The amorphous character of the new compound suggests that it will have better bioavailability. The dissolution study indicated that this compound is hydrolyzed to produce cefalexin in water in a sustained manner, thus it will act as a prodrug in vivo. The release data fitted well into Highuchi model.

Conclusion: Various pharmaceutical properties essentially required for formulation of salicylidine-cefalexin-Zn(II)·2H2O into dosage forms were determined. This study has shown that the new drug would behave as a prodrug for cefalexin with better bioavailability.

Key words

cefalexin - cefalexin complexes - Schiff base complexes - zinc complexes
 

  • References

  • 1 Brown AG, Roberts SM. Recent advances in the chemistry of β-Lactam antibiotics. The Royal Society of Chemistry; London: 1984
    Google Scholar
  • 2 Brain EG, Eglington AJ, James BG et al. Structure – activity relationships in cephalosporins prepared from penicillins. 2. Analogues of cephalexin substituted in the 3-methyl group. J Med Chem 1997; 20: 1086-1090
    PubMedGoogle Scholar
  • 3 Balkan A, Ertan M, Saraç S et al. Synthesis and antimicrobial activities of some new tetrahydro-2H-1,3,5-thiadiazine-2-thione derivatives of cephalexin. Arzneimittel Forschung 1990; 40: 1246-1249
    PubMedGoogle Scholar
  • 4 Hornyák M, Hartmann JF, Sztaricskai FJ et al. Beta-lactam antibiotics functionalized with gem-bisphosphonates. Acta Pharm Hung 1999; 69: 213-217
    PubMedGoogle Scholar
  • 5 Iqbal MS, Ahmad AR, Sabir M et al. Preparation, characterization and biological evaluation of copper(II) and zinc(II) complexes with cephalexin. J Pharm Pharmacol 1999; 51: 371-375
    CrossrefPubMedGoogle Scholar
  • 6 Iqbal MS, Bukhari IH, Arif M. Preparation, characterization and biological evaluation of copper(II) and zinc(II) complexes with Schiff bases derived from amoxicillin and cephalexin. Appl Organometal Chem 2005; 19: 864-869
    CrossrefPubMedGoogle Scholar
  • 7 Baudry DB, Dormond A, Durisa F et al. Lanthanide bis (trifluoromethanesulfonyl) amides, synthesis, characterization and catalytic activity. J Fluorine Chem 2003; 121: 233-238
    CrossrefPubMedGoogle Scholar
  • 8 Okhamafe AO, Azubuike CPC. Direct compression studies on low-cost cellulose derived from maize cobs. J Pharm Sci & Pharm Prac 1994; 1: 26-29
    PubMedGoogle Scholar
  • 9 Carr RL. Classifying flow properties of solids. Chem Eng 1965; 72: 69-72
    PubMedGoogle Scholar
  • 10 Hausner HH. Friction conditions in a mass of metal powders. Int J Powder Metall 1967; 3: 7-13
    PubMedGoogle Scholar
  • 11 Krycer I, Pope DG, Hersey JA. An evaluation of the techniques employed to investigate powder compaction behavior. Int J Pharm 1982; 12: 113-134
    CrossrefPubMedGoogle Scholar
  • 12 Heckel RW. An analysis of powder compaction phenomena. Trans Metall Soc AIME 1961; 221: 1001-1008
    PubMedGoogle Scholar
  • 13 Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm 2001; 220: 77-83
    CrossrefPubMedGoogle Scholar
  • 14 Yang W, Johnston KP, Williams III RO. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm 2010; 75: 33-41
    CrossrefPubMedGoogle Scholar
  • 15 Shah RB, Tawakkul MA, Khan MA. Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmSciTech 2008; 9: 250-258
    CrossrefPubMedGoogle Scholar
  • 16 Sebhatu T, Alderborn G. Relationships between the effective interparticulate contact area and the tensile strength of tablets of amorphous and crystalline lactose of varying particle size. Eur J Pharm Sci 1999; 8: 235-242
    CrossrefPubMedGoogle Scholar
  • 17 Rees JE, Hersey JA. The strength of compacts containing moisture. Pharm Acta Helv 1972; 47: 235-243
    PubMedGoogle Scholar